These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 30860605)
1. Characterization of triple-negative breast cancer preclinical models provides functional evidence of metastatic progression. Arroyo-Crespo JJ; Armiñán A; Charbonnier D; Deladriere C; Palomino-Schätzlein M; Lamas-Domingo R; Forteza J; Pineda-Lucena A; Vicent MJ Int J Cancer; 2019 Oct; 145(8):2267-2281. PubMed ID: 30860605 [TBL] [Abstract][Full Text] [Related]
2. FGF13 promotes metastasis of triple-negative breast cancer. Johnstone CN; Pattison AD; Harrison PF; Powell DR; Lock P; Ernst M; Anderson RL; Beilharz TH Int J Cancer; 2020 Jul; 147(1):230-243. PubMed ID: 31957002 [TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer. Steenbrugge J; Breyne K; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Colpaert C; Vermeulen P; Van Laere S; Meyer E J Exp Clin Cancer Res; 2018 Aug; 37(1):191. PubMed ID: 30111338 [TBL] [Abstract][Full Text] [Related]
4. Phloridzin docosahexaenoate, a novel fatty acid ester of a plant polyphenol, inhibits mammary carcinoma cell metastasis. Fernando W; Coyle K; Marcato P; Vasantha Rupasinghe HP; Hoskin DW Cancer Lett; 2019 Nov; 465():68-81. PubMed ID: 31473253 [TBL] [Abstract][Full Text] [Related]
5. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer. Ring A; Kaur P; Lang JE BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919 [TBL] [Abstract][Full Text] [Related]
6. Tumor-targeting adenovirus OBP-401 inhibits primary and metastatic tumor growth of triple-negative breast cancer in orthotopic nude-mouse models. Yano S; Takehara K; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM Oncotarget; 2016 Dec; 7(51):85273-85282. PubMed ID: 27863373 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the Adipose and Luminal Mammary Gland Compartment as Orthotopic Inoculation Sites in a 4T1-Based Immunocompetent Preclinical Model for Triple-Negative Breast Cancer. Steenbrugge J; Breyne K; Denies S; Dekimpe M; Demeyere K; De Wever O; Vermeulen P; Van Laere S; Sanders NN; Meyer E J Mammary Gland Biol Neoplasia; 2016 Dec; 21(3-4):113-122. PubMed ID: 27714576 [TBL] [Abstract][Full Text] [Related]
8. In Vivo Selection of Intermediately- and Highly-Malignant Variants of Triple-negative Breast Cancer in Orthotopic Nude Mouse Models. Yano S; Takehara K; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM Anticancer Res; 2016 Dec; 36(12):6273-6277. PubMed ID: 27919946 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models. Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216 [TBL] [Abstract][Full Text] [Related]
10. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer. Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870 [TBL] [Abstract][Full Text] [Related]
11. In Vivo Isolation of a Highly-aggressive Variant of Triple-negative Human Breast Cancer MDA-MB-231 Using Serial Orthotopic Transplantation. Yano S; Takehara K; Miwa S; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM Anticancer Res; 2016 Aug; 36(8):3817-20. PubMed ID: 27466482 [TBL] [Abstract][Full Text] [Related]
12. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer. Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer. Reguera-Nuñez E; Xu P; Chow A; Man S; Hilberg F; Kerbel RS J Exp Clin Cancer Res; 2019 Jan; 38(1):16. PubMed ID: 30635009 [TBL] [Abstract][Full Text] [Related]
14. Metabolic Response of Triple-Negative Breast Cancer to Folate Restriction. Coleman MF; O'Flanagan CH; Pfeil AJ; Chen X; Pearce JB; Sumner S; Krupenko SA; Hursting SD Nutrients; 2021 May; 13(5):. PubMed ID: 34068120 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Tumor Recurrence After Resection of Highly- and Poorly-Metastatic Triple-negative Breast Cancer in Orthotopic Nude-Mouse Models. Yano S; Takehara K; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Fujiwara T; Bouvet M; Hoffman RM Anticancer Res; 2017 Jan; 37(1):57-60. PubMed ID: 28011473 [TBL] [Abstract][Full Text] [Related]
16. Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice. Fricke IB; De Souza R; Costa Ayub L; Francia G; Kerbel R; Jaffray DA; Zheng J PLoS One; 2018; 13(5):e0196892. PubMed ID: 29723251 [TBL] [Abstract][Full Text] [Related]
18. In vivo magnetic resonance imaging investigating the development of experimental brain metastases due to triple negative breast cancer. Hamilton AM; Foster PJ Clin Exp Metastasis; 2017 Feb; 34(2):133-140. PubMed ID: 28108861 [TBL] [Abstract][Full Text] [Related]
19. Comparative Profiling of Metastatic 4T1- vs. Non-metastatic Py230-Based Mammary Tumors in an Intraductal Model for Triple-Negative Breast Cancer. Steenbrugge J; Vander Elst N; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Dirix L; Van Laere S; Meyer E Front Immunol; 2019; 10():2928. PubMed ID: 31921184 [TBL] [Abstract][Full Text] [Related]
20. The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice. Buijs JT; Laghmani EH; van den Akker RFP; Tieken C; Vletter EM; van der Molen KM; Crooijmans JJ; Kroone C; Le Dévédec SE; van der Pluijm G; Versteeg HH J Thromb Haemost; 2019 Jun; 17(6):951-963. PubMed ID: 30929299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]